Exceptional 6-month data from Xeltis’ FIH aXess vascular conduit trial published in Journal of Vascular Access

In six-month data from the FIH trial, the aXess vascular conduit demonstrated high patency rates (80% primary patency, 100% secondary patency). At six months, a 0% infection rate and low re-intervention rates were reported, resulting in a highly favorable safety profile. Hemodialysis was successfully performed through the graft, and compared to current standard of care measures, which typically show lower rates of patency combined with a greater risk of infection or rejection, aXess demonstrated extremely promising results.

The trial is ongoing, with outstanding 12-month data presented by Professor Dr. Frans Moll at the VEITHSymposium 2023.